Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
Conditions: Angiosarcoma Interventions: Other: Observational Sponsors: Italian Sarcoma Group Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Conditions: Leiomyosarcoma; Liposarcoma; Synovial Sarcoma; Angiosarcoma; Undifferentiated Pleomorphic Sarcoma; Epithelioid Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Fibrosarcoma; Pleomorphic Rhabdomyosarcoma; Endometrial Stromal Sarcoma; Desmoplastic Small Round Cell Tumor Interventions: Biological: MASCT-I; Drug: Doxorubicin; Drug: Ifosfamide Sponsors: HRYZ Biotech Co. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Conditions: Soft Tissue Sarcoma Adult; Angiosarcoma; Undifferentiated Pleomorphic Sarcoma Interventions: Drug: Propranolol; Drug: Pembrolizumab Sponsors: Niels Junker; Aarhus University Hospital; Oslo University Hospital; Karolinska University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2023 Category: Research Source Type: clinical trials
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Conditions: Cutaneous Squamous Cell Carcinoma; SCC - Squamous Cell Carcinoma; Basal Cell Carcinoma; BCC; BCC - Basal Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Sebaceous Carcinoma; Extramammary Paget Disease; Kaposi Sarcoma; Head and Neck Squamous C ell Carcinoma; HNSCC; Adnexal Carcinoma; Angiosarcoma; Cutaneous Neoplasm; Advanced Cancer; Metastatic Cancer; Refractory Cancer; Solid Tumor Interventions: Biological: MQ719; Drug: Pembrolizumab Sponsor: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 15, 2023 Category: Research Source Type: clinical trials
